SpyGlass Pharma, Inc. SGP
Set alert
34.85 USD +1.20 +3.58%
As of Nov 3, 1:38 PM ET
34.08 Day range 35.09
17.06 52-week range 35.09
- YTD
- +31.99%
- 1 year
- +31.99%
- Open
- 34.08
- Prev close
- 33.64
- Mkt cap
- 1.17B
- Vol
- 80.30K
- Avg vol
- 102.06K
- EPS
- -2.51
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 34.08
- High
- 35.09
- Forward P/E
- -11.95
- Beta
- 0.00
- Short ratio
- 9.43
- Inst. own
- 94.68%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 27.23
- 200-d avg
- 24.36
- 1y target
- 44.00
6M chart
Events in this range
- May 15, 2026Earnings: -0.69; estimate -0.67; surprise -2.99%
- Aug 6, 2026Earnings: -0.59; estimate -0.51442; surprise -14.69%
- Aug 14, 2026Rating: Raymond James · — → Outperform
- Oct 5, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Oct 21, 2026Rating: HC Wainwright & Co. · Buy → Buy
Signals (26)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Oct 27, 2026 | 1 week ago |
| SMA: Bullish | Oct 21, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 20, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 2, 2026 | 1 month ago |
| SMA: Bullish | Sep 30, 2026 | 1 month ago |
| SMA: Bearish | Sep 29, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 9, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 3, 2026 | 2 months ago |
| RSI: Overbought | Sep 2, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 26, 2026 | 2 months ago |
| RSI: Overbought | Aug 19, 2026 | 2 months ago |
| RSI: Overbought | Aug 14, 2026 | 2 months ago |
| RSI: Overbought | Aug 7, 2026 | 2 months ago |
| SMA: Bullish | Jul 30, 2026 | 3 months ago |
| SMA: Bullish | Jul 21, 2026 | 3 months ago |
| SMA: Bearish | Jul 17, 2026 | 3 months ago |
| SMA: Bullish | Jul 16, 2026 | 3 months ago |
| SMA: Bearish | Jul 13, 2026 | 3 months ago |
| SMA: Bullish | Jul 10, 2026 | 3 months ago |
| SMA: Bearish | Jul 1, 2026 | 4 months ago |
Newest 20 of 26.
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 44.00 +26.3% upside
Now 34.85
- Target (low)
- 37.00
- Target (mean)
- 44.00
- Target (high)
- 62.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy1
- Buy5
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 6
- 1 month ago 6
- 2 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.62247 | -0.71 – -0.52481 | 0.00 | 0.0% | 0 | 0.0% | 6 |
| Next quarter | -0.65294 | -0.77 – -0.54762 | 0.00 | 0.0% | 0 | 0.0% | 6 |
| Current year | -2.50 | -2.57 – -2.31 | -1.96 | -27.5% | 0 | 0.0% | 6 |
| Next year | -2.81 | -3.45 – -1.95 | -2.50 | -12.6% | 0 | 0.0% | 6 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 21, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 5, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 14, 2026 | Raymond James | Initiated | — | Outperform |
| Mar 10, 2026 | HC Wainwright & Co. | Initiated | — | Buy |
| Mar 3, 2026 | Citigroup | Initiated | — | Buy |
| Mar 3, 2026 | Leerink Partners | Initiated | — | Outperform |
| Mar 3, 2026 | Jefferies | Initiated | — | Buy |
| Mar 3, 2026 | Stifel | Initiated | — | Buy |